ClinicalTrials.gg
RecruitingNCT07396857Updated Apr 13, 2026

The Role of EDHFs on Blood Pressure Following a Bout of Prolonged Sitting

An interventional study of Placebo and Fluconazole 150 mg in Cardiovascular, sponsored by Université de Sherbrooke. Recruiting at 1 site in Canada. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-13.

Sponsored by Université de Sherbrooke · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Nov 2025, registered Feb 2026).
  • Started Nov 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 73 studies in Sedentary Behavior with a site in Canada — 18 open to participants now, 19 under way, none of them phase 3. Sedentary Behavior · Canada.

Planned enrollment
43rd of 69
40 · median 50
Started
2025
with 4 others
No phase
67 of 73
18 open now
Primary completion
2026-12
later than 10 of 18 live
Registered
71st of 73
by date

Among the 73 studies in Sedentary Behavior with a site in Canada, this one is the 43rd largest by planned enrollment of the 69 interventional ones that give a count, is one of 5 that started in 2025, is one of 67 with no phase, reaches primary completion later than 10 of the 18 other live ones, and was the 71st registered.

Sedentary Behavior

1,276 studies on the registry are indexed under Sedentary Behavior; 292 are open to participants now.

Browse Sedentary Behavior studies →

Open to participants now

18 of the 73 studies in Sedentary Behavior with a site in Canada are open now. Recruiting first, the newest first:

12 more — sign in →

All 18 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 184 Sedentary Behavior studies recruiting now, 77 (42%) set no upper age limit and 82 (45%) stop at 75 or younger; 30 take children under 18; 97 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 73 studies in Sedentary Behavior with a site in Canada, or all of them as a file.
02

Study summary

Canadians spend most of their day in sedentary postures (i.e., sitting, lying, reclining). While the beneficial impacts of physical activity on the heart are well-established, less is known about the consequences during time spent in sedentary postures. Currently, we know that spending time in a bout of uninterrupted sitting disrupts blood pressure regulation. However, it is unknown if there are any 'carry over' effects following uninterrupted sitting bouts (i.e., over the next 24-hours). The release of chemicals from arteries controls how stiff or relaxed they are and is important for controlling blood pressure. This is especially true for arteries directly impacted by sitting (e.g., the popliteal artery behind the knee) and that send blood to the brain (e.g., the carotid artery). We have also established that endothelial-derived hyperpolarizing factors (EDHF, chemicals that relax the artery) are important for the relaxation of the artery the popliteal artery. However, we do not know if the effects of EDHFs on this artery are decreased during or after a bout of uninterrupted sitting. A bout of prolonged sitting also causes blood pressure and fluctuations in blood pressure to increase. Importantly, we reported that fluctuations in blood pressure caused by sitting are higher in young males versus females, but average blood pressure was higher among females. These findings suggest that sitting exerts sex differences in the control of blood pressure. Importantly, these effects were only demonstrated during the 2-hour bout of sitting. As such, it is unknown whether blood pressure is negatively impacted after prolonged sitting. The proposed study will determine the impact of EDHFs on blood pressure regulation following a 2-hour bout of prolonged sitting among a group of healthy males and females. Continuous heart rate (via electrocardiogram) and blood pressure (via finger cuff), as well as blood flow from the common carotid artery (in the neck), middle cerebral artery (in the brain) and popliteal artery (behind the knee) will be measured before and after sitting (via ultrasound). The ability of the popliteal artery to relax will be assessed using ultrasound following the release of a pressure cuff. Finally, 24-hour blood pressure and heart rate will be recorded after sitting using a monitor worn for 24-hours. The role of EDHFs will be investigated by comparing 1) baseline blood flow and blood pressure responses (no sitting), 2) blood pressure responses following a 2-hour bout of sitting, and 3) the blood pressure responses following a 2-hour bout of sitting while suppressing the release of EDHFs (via fluconazole ingestion).

03

Conditions studied

  • Cardiovascular

Browse trials for

Keywords

  • Arterial function
  • Sedentary time
  • Sex differences
  • Vasoactive substances
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Are between the ages of 18-65.
  • Have a of \<40kg/m2 (non-obese).
  • Have not smoked nicotine or marijuana-containing products most days of the week within the past 6 months.
  • Have not been diagnosed with a cardiovascular, cerebrovascular, respiratory, or metabolic disease.
  • Are normotensive.
  • Are not currently taking any medications for cardiovascular, metabolic, pulmonary, or neurological disorders, or taking sildenafil regularly.
  • Are not allergic to the adhesive used to secure the activPAL activity monitors.
  • Are not pregnant or breastfeeding.
  • Are not regularly taking any of the following: another anti-fungal, heartburn medications containing cisapride (e.g., Propulsid), depression medications containing amitriptyline (e.g., Elavil) or nortriptyline (e.g., Pamelor), erythromycin (antibiotic), lipid lower medications (i.e., statins), non-steroidal anti-inflammatory drugs (e.g., ibuprofen), or vitamin A supplements.

Exclusion criteria

Exclusion Criteria:

  • o Younger than 18 years old. Individuals younger than 18 demonstrate more variable peak FMD responses and require multiple assessments to determine peak response.

    • Over the age of 65. There are age-related impacts on arterial function and the responses to sitting.
    • of >40 kg/m2 (i.e., obese II category)(6-8).
    • Smoked nicotine or marijuana-containing products most days of the week within the past 6 months. Cardiovascular health for participants who smoke is poor compared to those who do not smoke, which will negatively impact our arterial function outcomes.
    • Have been diagnosed with a cardiovascular, cerebrovascular, respiratory, or metabolic disease. Such conditions impact our assessments of arterial health. The results of unhealthy participants are not of interest in this study.
    • Hypertension (seated resting systolic pressure >139 mmHg and/or diastolic pressure >89 mmHg). Hypertensive individuals have impairments in artery health, which will affect their baseline artery health measures.
    • Hypotensive (seated resting systolic pressure \<90 mmHg and/or diastolic pressure \<60 mmHg). Hypotensive people are more likely to experience further reductions in blood pressure during the sitting protocol, which will increase the risk of fainting and/or dizziness.
    • Have a history of fainting and/or dizziness during sitting or standing.
    • Prescribed medications for cardiovascular, metabolic, pulmonary, or neurological disorders. This includes people using hormone replacement therapy. These medications will interfere with our assessments and interpretation of arterial health.
    • Have a known allergy to the clear medical adhesive used to secure the activPAL activity monitors.
    • Females who are pregnant or breastfeeding. Pregnant and breastfeeding females are ineligible to participate. This is due to the known increases in arterial vasodilation associated with pregnancy related sex hormones.
    • Currently or recently (within the past 6 months) regularly taking sildenafil or other medications that increase the relaxing effects of nitric oxide in arteries. Such medication will influence artery blood flow and flow-mediated dilation responses.
    • Are regularly taking any of the following: another anti-fungal, heartburn medications containing cisapride (e.g., Propulsid), depression medications containing amitriptyline (e.g., Elavil) or nortriptyline (e.g., Pamelor), erythromycin (antibiotic), lipid lower medications (i.e., statins), non-steroidal anti-inflammatory drugs (e.g., ibuprofen), or vitamin A supplements. These are to minimize the chance of a participant experiencing an adverse reaction to the fluconazole tablet.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Males

    Drug: Placebo · Drug: Fluconazole 150 mg

  • Experimental
    Females

    Drug: Placebo · Drug: Fluconazole 150 mg

Interventions

  • DrugPlacebo

    Participants will take a placebo sugar pill before and after a bout of prolonged sitting as a control session.

  • DrugFluconazoleStudies of FluconazoleFluconazole pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Participants will take 150mg of fluconazole, an EDHF inhibitor before and after a bout of prolonged sitting.

06

What researchers measure

Primary outcomes

  1. Popliteal Low-Flow Mediated Constriction

    During a period of distal cuff-induced ischemia, the endothelial-dependent vasoconstrictor response will be assessed via Duplex ultrasonography. The popliteal artery will be imaged slightly above the popliteal fossa. The L-FMC response will be quantified as the percent reduction in arterial diameter from baseline to the nadir diameter from the last 30-s of a 5-min distal cuff occlusion period.

    Time frame: Before prolonged sitting, after 1-hour of sitting, after 2-hours of sitting

  2. Acute Blood Pressure

    Beat-by-beat systolic (SBP) and diastolic (DBP) blood pressure will be measured using finger photoplethysmography for 20 minutes before the bout of prolonged sitting, 20 minutes after 1-hour of sitting, and 20 minutes after 2-hours of sitting. Mean arterial pressure will be quantified as 1/3 SBP + 2/3 DBP.

    Time frame: Before prolonged sitting, after 1-hour of sitting, after 2-hours of sitting.

  3. Ambulatory Blood Pressure

    Using an ABPMpro Ambulatory Blood Pressure Monitors, habitual blood pressure will be measured every 20-minutes during waking hours, and every 30-minutes during sleeping hours.

    Time frame: This will be worn for a 24-hour period before the first prolonged sitting session, and for 24-hours after each bout of prolonged sitting.

Secondary outcomes

  1. Carotid Artery Blood Flow Velocity

    Blood flow velocity will be measured immediately prior to the bifurcation in the common carotid artery using Duplex ultrasonography for 5 minutes.

    Time frame: Before prolonged sitting, after 1-hour of sitting, after 2-hours of sitting.

  2. Middle Cerebral Artery Velocity

    Blood flow velocity will be measured via transcranial Doppler over the trans-temporal window for 5 minutes.

    Time frame: Before prolonged sitting, after 1-hour of sitting, after 2-hours of sitting.

  3. Popliteal Flow Mediated Dilation (FMD)

    Following a period of distal cuff induced ischemia, the endothelial-dependent vasodilator response will be assessed via Duplex ultrasonography. The popliteal artery will be imaged slightly above the popliteal fossa. The FMD response will be quantified as the percent increase in arterial diameter from baseline to the peak diameter following the release of the distal cuff.

    Time frame: Before prolonged sitting, after 1-hour of sitting, after 2-hours of sitting.

  4. Physical Activity Behaviour Questionnaire

    A subjective questionnaire that provides information regarding habitual physical activity and sedentary behaviours.

    Time frame: At time of study enrolment

  5. Heart Rate Variability (HRV)

    Heart rate will be determined using cardiac intervals from a lead II electrocardiography during prolonged sitting, and from the built-in electrocardiogram in the ambulatory blood pressure monitor. HRV will be derived from these waveforms using an offline HRV analysis module. Time-domain (I.e., RMSSD), frequency-domain, low frequency (LF) power, high frequency (HF) power, and the LF/HF ratio will be quantified for each participant.

    Time frame: Acute: Before prolonged sitting, after 1-hour of sitting, after 2-hours of sitting. Ambulatory: 24-hours at baseline, 24-hours after each bout of prolonged sitting.

  6. Carotid Intima Media Thickness (cIMT)

    cIMT will be determined from a 5-minute recording of the carotid artery, imaged prior to the bifurcation using Duplex ultrasonography.

    Time frame: Before prolonged sitting, after 1-hour of sitting, after 2-hours of sitting.

  7. Carotid Artery Distensibility

    Distensibility will be determined from 5-minutes of recorded carotid artery imaging via Duplex ultrasonography, and will be calculated as the difference between average arterial diameter during systole and diastole.

    Time frame: Before prolonged sitting, after 1-hour of sitting, after 2-hours of sitting.

  8. Blood Pressure Varibility (BPV)

    Beat-by-beat BPV during sitting will be quantified using the blood pressure measurements derived from finger photoplethysmography. This will be calculated as the average absolute difference between successive finger blood pressure measurements, for systolic blood pressure, diastolic blood pressure, and mean arterial pressure. Ambulatory BPV will be quantified from the 24-hour blood pressure monitors.

    Time frame: Acute: Before prolonged sitting, after 1-hour of sitting, after 2-hours of sitting. Ambulatory: 24-hours at baseline, 24-hours after each bout of prolonged sitting.

  9. Cardiovagal Baroreflex Sensitivity (cvBRS)

    cvBRS will be quantified from beat-by-beat systolic blood pressure (SBP) and R-R intervals in a cvBRS software. cvBRS outcomes will be quantified from a minimum of 3 sequences in which beat-by-beat SBP changes were ≥1 mmHg and changes in R-R interval were ≥ 1 ms. Overall cvBRS is represented by the average slope of SBP and R-R interval regressions for the pooled sequences, and reported separately for both up and down sequences. Baroreflex effectiveness index (BEI) will be measured as the ratio of the number of SBP ramp-induced changes in RR interval to the total number of SBP ramps observed. This will be reported separately for both up and down sequences. This will be measured over a 20-minute time period.

    Time frame: Before prolonged sitting, after 1 hour of sitting, after 2-hours of sitting.

  10. Habitual Activity

    Habitual activity will be measured using activPAL inclinometer-accelerometers positioned on the torso, thigh, and calf. Monitors will be waterproofed and attached 24-hr/day for 8 days via clear medical adhesive. Physical activity will be determined via validated, custom software that was developed and openly published by our group.

    Time frame: Before first bout of sitting, after each bout of sitting.

  11. Habitual Postures

    Habitual postures will be measured using activPAL inclinometer-accelerometers positioned on the torso, thigh, and calf. Monitors will be waterproofed and attached 24-hr/day for 8 days via clear medical adhesive. Time spent in postures (e.g., sitting versus lying time) will be determined via validated, custom software that was developed and openly published by our group.

    Time frame: Before first bout of sitting, after each bout of sitting.

  12. Baseline Arterial Diameters

    Arterial diameter of the popliteal and carotid arteries will be determined via Duplex ultrasonography over a minimum of 2-minutes.

    Time frame: Before prolonged sitting, after 1-hour of sitting, after 2-hours of sitting.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Turner JR, Viera AJ, Shimbo D. Ambulatory blood pressure monitoring in clinical practice: a review. Am J Med. 2015 Jan;128(1):14-20. doi: 10.1016/j.amjmed.2014.07.021. Epub 2014 Aug 12. PubMed 25107387 ↗
  • Pellerine LP, Miller K, Frayne RJ, O'Brien MW. Characterizing objective and self-report habitual physical activity and sedentary time in outpatients with an acquired brain injury. Sports Med Health Sci. 2024 Feb 10;6(4):338-343. doi: 10.1016/j.smhs.2024.02.001. eCollection 2024 Dec. PubMed 39309460 ↗
  • Bays HE, Toth PP, Kris-Etherton PM, Abate N, Aronne LJ, Brown WV, Gonzalez-Campoy JM, Jones SR, Kumar R, La Forge R, Samuel VT. Obesity, adiposity, and dyslipidemia: a consensus statement from the National Lipid Association. J Clin Lipidol. 2013 Jul-Aug;7(4):304-83. doi: 10.1016/j.jacl.2013.04.001. Epub 2013 May 31. PubMed 23890517 ↗
  • O'Brien MW, Johns JA, Al-Hinnawi A, Kimmerly DS. Popliteal flow-mediated dilatory responses to an acute bout of prolonged sitting between earlier and later phases of natural menstrual and oral contraceptive pill cycles. J Appl Physiol (1985). 2020 Oct 1;129(4):637-645. doi: 10.1152/japplphysiol.00424.2020. Epub 2020 Aug 13. PubMed 32790597 ↗
  • Liu H, O'Brien MW, Wu Y, Bustamante CM, Kimmerly DS. An acute bout of prolonged sitting blunts popliteal endothelium-independent dilation in young, healthy adults. J Appl Physiol (1985). 2023 Mar 1;134(3):521-528. doi: 10.1152/japplphysiol.00712.2022. Epub 2023 Jan 19. PubMed 36656984 ↗
  • Ishikura F, Beppu S, Hamada T, Khandheria BK, Seward JB, Nehra A. Effects of sildenafil citrate (Viagra) combined with nitrate on the heart. Circulation. 2000 Nov 14;102(20):2516-21. doi: 10.1161/01.cir.102.20.2516. PubMed 11076826 ↗
  • Lopes van Balen VA, van Gansewinkel TAG, de Haas S, van Kuijk SMJ, van Drongelen J, Ghossein-Doha C, Spaanderman MEA. Physiological adaptation of endothelial function to pregnancy: systematic review and meta-analysis. Ultrasound Obstet Gynecol. 2017 Dec;50(6):697-708. doi: 10.1002/uog.17431. PubMed 28170124 ↗
  • Puranik R, Celermajer DS. Smoking and endothelial function. Prog Cardiovasc Dis. 2003 May-Jun;45(6):443-58. doi: 10.1053/pcad.2003.YPCAD13. PubMed 12800127 ↗
  • Jarvisalo MJ, Ronnemaa T, Volanen I, Kaitosaari T, Kallio K, Hartiala JJ, Irjala K, Viikari JS, Simell O, Raitakari OT. Brachial artery dilatation responses in healthy children and adolescents. Am J Physiol Heart Circ Physiol. 2002 Jan;282(1):H87-92. doi: 10.1152/ajpheart.2002.282.1.H87. PubMed 11748051 ↗
  • Tomiyama AJ, Hunger JM, Nguyen-Cuu J, Wells C. Misclassification of cardiometabolic health when using body mass index categories in NHANES 2005-2012. Int J Obes (Lond). 2016 May;40(5):883-6. doi: 10.1038/ijo.2016.17. Epub 2016 Feb 4. PubMed 26841729 ↗
  • Seals DR, Jablonski KL, Donato AJ. Aging and vascular endothelial function in humans. Clin Sci (Lond). 2011 May;120(9):357-75. doi: 10.1042/CS20100476. PubMed 21244363 ↗
  • Paterson C, Fryer S, Stone K, Zieff G, Turner L, Stoner L. The Effects of Acute Exposure to Prolonged Sitting, with and Without Interruption, on Peripheral Blood Pressure Among Adults: A Systematic Review and Meta-Analysis. Sports Med. 2022 Jun;52(6):1369-1383. doi: 10.1007/s40279-021-01614-7. Epub 2021 Dec 21. PubMed 34932203 ↗
  • Petterson JL, O'Brien MW, Johns JA, Chiasson J, Kimmerly DS. Influence of prostaglandins and endothelial-derived hyperpolarizing factors on brachial and popliteal endothelial-dependent function in young adults. J Appl Physiol (1985). 2021 Jan 1;130(1):17-25. doi: 10.1152/japplphysiol.00698.2020. Epub 2020 Oct 29. PubMed 33119467 ↗
  • Hall JE. Integration and regulation of cardiovascular function. Am J Physiol. 1999 Dec;277(6 Pt 2):S174-86. doi: 10.1152/advances.1999.277.6.S174. PubMed 10644245 ↗
  • Tremblay MS, Aubert S, Barnes JD, Saunders TJ, Carson V, Latimer-Cheung AE, Chastin SFM, Altenburg TM, Chinapaw MJM; SBRN Terminology Consensus Project Participants. Sedentary Behavior Research Network (SBRN) - Terminology Consensus Project process and outcome. Int J Behav Nutr Phys Act. 2017 Jun 10;14(1):75. doi: 10.1186/s12966-017-0525-8. PubMed 28599680 ↗
  • Sedentary Behaviour Research Network. Letter to the editor: standardized use of the terms "sedentary" and "sedentary behaviours". Appl Physiol Nutr Metab. 2012 Jun;37(3):540-2. doi: 10.1139/h2012-024. Epub 2012 Apr 27. No abstract available. PubMed 22540258 ↗
  • Herman KM, Saunders TJ. Sedentary behaviours among adults across Canada. Can J Public Health. 2016 Dec 27;107(4-5):e438-e446. doi: 10.17269/cjph.107.5587. PubMed 28026711 ↗
  • Waghorn J, Liu H, Wu Y, Rayner SE, Kimmerly DS, O'Brien MW. A Single Bout of Prolonged Sitting Augments Very Short-Term Blood Pressure Variability. Am J Hypertens. 2024 Aug 14;37(9):700-707. doi: 10.1093/ajh/hpae055. PubMed 38703068 ↗

Individual participant data

Plan to share: No — IPD will not be shared to maintain privacy and confidentiality of the participants.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Dec 2026, 13 months after the start.

Of 736 non-industry interventional studies with no phase under Sedentary Behavior, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 30. This study's planned 13 months is close to that.

Counting every sponsor, half of 744 studies reached it within 14 months; a quarter within 6 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 2, 2026
First posted
Feb 9, 2026
StartActual
Nov 1, 2025
Primary completionEst.
Dec 15, 2026
CompletionEst.
Dec 15, 2026
Last update
Apr 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07396857
Collaborators
Dalhousie University
Responsible party
Myles William O'Brien (Assistant Professor, Université de Sherbrooke) — Principal investigator
First posted
Feb 9, 2026
Start date
Nov 1, 2025
Primary completion
Dec 15, 2026 (estimated)
Completion
Dec 15, 2026 (estimated)
Last update
Apr 13, 2026

Study contacts

Molly K Courish, MSc, PhD(s)
Contact
molly.courish@dal.ca
902-818-0783
Myles W O'Brien, PhD
principal investigator · Université de Sherbrooke

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fluconazole

Start the discussion